美罗华
医学
免疫学
CD20
自身抗体
单克隆抗体
疾病
单克隆
红斑狼疮
自身免疫
发病机制
B细胞
抗体
贝里穆马布
系统性红斑狼疮
B细胞激活因子
内科学
作者
Kavina Shah,Mark S. Cragg,Maria Leandro,Venkat Reddy
出处
期刊:Biologicals
[Elsevier]
日期:2021-01-01
卷期号:69: 1-14
被引量:14
标识
DOI:10.1016/j.biologicals.2020.11.002
摘要
Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition with a wide spectrum of disease manifestations and severities, resulting in significant morbidity and mortality. The aetiopathogenesis of SLE is complex. Young women and certain ethnicities are commonly affected, suggesting a significant hormonal and genetic influence. Diverse immunological abnormalities have been described. A characteristic abnormality is the presence of autoantibodies, implicating a central role for B cells in disease pathogenesis and/or perpetuation. Whilst conventional therapies have improved outcomes, a great unmet need remains. Recently, biological therapies are being explored. B-cell depletion therapy with rituximab has been in use off-label for nearly two decades. Inconsistent results between uncontrolled and controlled studies have raised doubts about its efficacy. In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb), rituximab, will be explored including an evaluation of clinical and trial experience. Finally, we will discuss the mechanistic basis for considering alternative anti-CD20 mAbs.
科研通智能强力驱动
Strongly Powered by AbleSci AI